TABLE 2.

Pulmonary-Related Characteristics at Study Enrollment

CharacteristicPlacebo (n = 16)Fluticasone (n = 16)P Value
Age at enrollment, d45.4 ± 1044.8 ± 11.89
Mechanical ventilation with endotracheal intubation, %5 (31)5 (31)1.0
Nasopharyngeal CPAP, %4 (25)3 (19).72
Fio20.30 ± 0.030.26 ± 0.03.009
Prior postnatal dexamethasone, %10 (63)12 (75).53
Duration of dexamethasone, d, median (range)3 (2–40)3 (2–17)
Last day of dexamethasone dose before study day 0, d, median (range)−18 (−47 to −15)−15 (−45 to −10)
Previously inhaled corticosteroids, %2 (12)1 (6)1.0
Duration of inhaled corticosteroid before study day 022 d and 3 d20 d
Last day of inhaled corticosteroid dose before study day 0Day −26 and −13Day −18
Diuretics, %*15 (94)15 (94)1.0
Caffeine, %*16 (100)16 (100)1.0
Inhaled salbutamol, %*4 (25)4 (25)1.0
  • CPAP indicates continuous positive airway pressure.

  • * Medications received during the full course of the study, some adjusted according to infant weight gain.